Merck spinoff Organon adds CFO, CIO from Allergan

Merck has named two C-suite executives for its upcoming Organon & Co. women’s health, legacy brand and biosimilars spinoff, it announced this week.

The Kenilworth-based drugmaker said in a news release that Matthew Walsh will serve as chief financial officer and Rachel Stahler will be chief information officer for Organon, which is on track to separate from the parent company in the first half of 2021.

Both will join Organon from Allergan, where Walsh was an executive vice president and CFO and Stahler was CIO. Walsh has also held executive positions with Catalent, while Stahler has served as a CIO for several companies.

“I am pleased to welcome Matt and Rachel to the recently appointed executive leadership team for Organon,” Kenneth Frazier, Merck’s chairman and CEO, said in a prepared statement. “Their deep expertise and pharmaceutical industry knowledge make them both important additions to the team at this pivotal moment in Organon’s preparation to become an independent company.”

Organon’s leadership team includes Chairman Carrie Cox and CEO Kevin Ali, among others.